SS Innovations International (NASDAQ: SSII) has reported significant growth in the adoption of its SSi Mantra surgical robotic system, with cumulative procedures reaching 14,103 as of September 8, 2026. This represents a 79% increase from 7,885 procedures at the end of 2025. The installed base of SSi Mantra systems has also expanded to 238 units, up 42% from 168 at year-end, and now spans 12 countries following recent launches in Colombia and Sri Lanka. The data, issued in a September 10 update, underscores the company's accelerating global footprint and the expanding clinical utility of its robotic platform.
The implications of this growth are substantial for the surgical robotics market, where Intuitive Surgical's da Vinci system has long dominated. SS Innovations is positioning SSi Mantra as a cost-effective alternative, and the rapid procedure growth suggests increasing surgeon acceptance and institutional adoption. The company also noted that approximately 1,500 physicians have been trained on the system, which is critical for driving sustained utilization and expanding into new surgical specialties. As more surgeons become proficient, the procedure count is likely to continue climbing, reinforcing the installed base's value and potentially leading to further orders.
Pediatric applications are emerging as a key differentiator. The company highlighted a robotic kidney procedure performed on a 45-day-old infant in India using 5-millimeter instruments. This case demonstrates the system's precision and versatility in minimally invasive pediatric surgery, a segment where few robotic options exist. Success in such complex, small-scale procedures could open additional pediatric indications and strengthen SSi Mantra's competitive edge.
Furthermore, SS Innovations reported 188 cumulative robotic telesurgeries as of August 31, including long-distance procedures connecting surgeons and patients across countries. Telesurgery has the potential to address surgeon shortages in remote or underserved regions, and the company's progress in this area positions it at the forefront of a trend that could reshape global surgical care delivery. Regulatory milestones are also on the horizon. The company expects the U.S. Food and Drug Administration to review its 510(k) submission by the end of Q1 2027 and believes EU CE marking for SSi Mantra could be obtained by the end of 2026. These clearances would unlock access to the world's two largest medical device markets, significantly broadening the company's addressable market and revenue potential.
For investors and industry observers, these developments signal that SS Innovations is transitioning from a regional player to a global contender. The combination of rapid procedure growth, geographic expansion, technological differentiation in pediatrics and telesurgery, and upcoming regulatory decisions creates a compelling narrative. If the company secures FDA and CE approvals on schedule, it could accelerate adoption in high-value markets, intensify competition, and potentially drive down costs for robotic surgery worldwide. For more details, see the Read More and the full release on www.newmediawire.com. Additional information about SSII is available at https://ibn.fm/SSII.
